Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: A call for action
Abstract
Acute cardiorenal syndrome (CRS), categorized as CRS type 1 and 3, is defined by the interplay of acute kidney injury or dysfunction and acute cardiac disease. For optimized diagnosis and management of CRS, strategies targeting multi-organ dysfunction must be adopted. Early diagnosis of acute CRS is important to enable timely initiation of appropriate treatment to prevent serious morbidity and mortality; however, traditional biomarkers are suboptimal. Over the past 2 decades, numerous biomarkers have been investigated for a better and more rapid diagnosis of CRS. Yet, the uptake of these contemporary biomarkers has been slow, possibly owing to the use of imperfect gold-standard reference tests. We believe that there is now scope for use of contemporary laboratory test panels to improve the diagnosis of acute CRS. In this review, we briefly discuss a proposed set of biomarkers for the diagnosis of type 1 and type 3 CRS.
Publication Title
American Heart Journal
Recommended Citation
Jefferies, J., Kovesdy, C., & Ronco, C. (2023). Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: A call for action. American Heart Journal, 261, 75-84. https://doi.org/10.1016/j.ahj.2023.03.007
